Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia

Therapy resistance is a major challenge in the treatment of cancer. Here, we performed CRISPR-Cas9 screens across a broad range of therapies used in acute myeloid leukemia to identify genomic determinants of drug response. Our screens uncover a selective dependency on RNA splicing factors whose loss...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer cell Vol. 41; no. 1; p. 164
Main Authors:	Wang, Eric, Pineda, Jose Mario Bello, Kim, Won Jun, Chen, Sisi, Bourcier, Jessie, Stahl, Maximilian, Hogg, Simon J, Bewersdorf, Jan Phillipp, Han, Cuijuan, Singer, Michael E, Cui, Daniel, Erickson, Caroline E, Tittley, Steven M, Penson, Alexander V, Knorr, Katherine, Stanley, Robert F, Rahman, Jahan, Krishnamoorthy, Gnana, Fagin, James A, Creger, Emily, McMillan, Elizabeth, Mak, Chi-Ching, Jarvis, Matthew, Bossard, Carine, Beaupre, Darrin M, Bradley, Robert K, Abdel-Wahab, Omar
Format:	Journal Article
Language:	English
Published:	United States 09.01.2023
Subjects:	Apoptosis - genetics Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cell Line, Tumor Humans Leukemia, Myeloid, Acute - genetics Myeloid Cell Leukemia Sequence 1 Protein - metabolism Protein-Tyrosine Kinases Proto-Oncogene Proteins c-bcl-2 RNA Splicing - genetics RNA-Binding Proteins - genetics CLK acute myeloid leukemia BCL2 XIAP venetoclax DYRK RBM10 RNA splicing
ISSN:	1878-3686, 1878-3686
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!